Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 15;62(16):2301-2306.
doi: 10.2169/internalmedicine.0789-22. Epub 2023 Jan 12.

A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance

Kazunori Adachi  1 , Shunsuke Kato  1 , Akira Koshino  1 , Kazuhiro Nagao  1 , Tomoya Sugiyama  1 , Takashi Yoshimine  1 , Yoshiharu Yamaguchi  1 , Shinya Izawa  1 , Wataru Ohashi  2 , Masahide Ebi  1 , Yasushi Funaki  1 , Naotaka Ogasawara  1 , Makoto Sasaki  1 , Kunio Kasugai  1
Affiliations

A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance

Kazunori Adachi et al. Intern Med. .

Abstract

Objective Vonoprazan (VPZ), clarithromycin (CAM), metronidazole (MNZ) and VPZ, MNZ, and sitafloxacin (STFX) regimen are all established Helicobacter pylori eradication therapies for patients with penicillin allergy in Japan. However, no study has assessed the efficacy of a VPZ, CAM, and MNZ (VCM) regimen in patients with clarithromycin resistance (CAM-R). We therefore assessed the efficacy of a VCM regimen for treating H. pylori infection in patients with CAM-R and penicillin allergy. Methods Fifty-three patients with penicillin allergy who received H. pylori eradication therapy were retrospectively analyzed. Eight patients received a 7-day proton-pump inhibitor, CAM, and MNZ (PCM) regimen; 35 patients [11 CAM-R, and 10 with clarithromycin sensitivity (CAM-S)] received 7-day VCM regimens; and 10 patients received 7-day VPZ, MNZ, and STFX (VMS) regimens. A 13C-urea breath test was used to determine eradication. The efficacy of eradication was evaluated via both intention-to-treat (ITT) and per-protocol (PP) analyses. Results According to ITT and PP analyses, eradication rates (ERs) with PCM, VCM, and VMS therapies were 50.0% and 50.0%, 94.3% and 100%, and 90% and 90%, respectively. Treatment was successful in all patients with CAM-S. For patients with CAM-R, treatment was successful in 10 patients, and 1 patient discontinued treatment owing to an adverse event. According to ITT and PP analyses, ERs were 90.9% and 100% in CAM-R, and were 100% and 100% in CAM-S, respectively. Conclusion The VCM regimen for H. pylori eradication may be a viable candidate therapy for patients with penicillin allergy, regardless of CAM-R.

Keywords: Helicobacter pylori; clarithromycin-resistance; eradication therapy; penicillin allergy; vonoprazan.

PubMed Disclaimer

Conflict of interest statement

The authors state that they have no Conflict of Interest (COI).

Figures

Figure 1.
Figure 1.
Flow diagram of patient selection, allocation, and patient outcomes. Two of the 55 potential patients declined Helicobactor pylori eradication therapy after the screening interview, leaving 53 patients as study participants. PCM: proton-pump inhibitor in combination with clarithromycin and metronidazole, VCM: vonoprazan in combination with clarithromycin and metronidazole, VMS: vonoprazan in combination with sitafloxacin and metronidazole
Figure 2.
Figure 2.
Eradication rates based on CAM susceptibility in VCM. CAM-R was seen in 11 patients, with 1 patient eventually withdrawing from the study, while CAM-S was seen in 10 patients. Eradication rates (ITT and PP) were 90.9% and 100% in CAM-R, and were 100% and 100% in CAM-S, respectively. CAM-R: clarithromycin resistance, CAM-S: clarithromycin sensitivity, ITT: intention-to-treat, PP: per-protocol, VCM: vonoprazan in combination with clarithromycin and metronidazole
See this image and copyright information in PMC

Comment in

References

    1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut 66: 6-30, 2017. - PubMed
    1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59: 1143-1153, 2010. - PubMed
    1. Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol 20: 665-672, 2014. - PMC - PubMed
    1. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 45: 4006-4010, 2007. - PMC - PubMed
    1. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 43: 514-533, 2016. - PMC - PubMed